The most recent PDS Biotechnology (PDSB) insider transaction: Deborah Ramsdell (Director) received 22,700 shares as a grant or award on Oct 18, 2026, reported on Form 4 on Oct 20, 2026. So far in the quarter ending Dec 31, 2026, insider holdings showed no net buying or selling.
In the last 12 months, insiders at PDS Biotechnology neither bought nor sold shares on the open market.
| # | Insider | Position | Direct | Indirect | Total | Share of Insiders | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Frank Bedu-Addo | President/Ceo | 690,866 | 0 | 690,866 | 83.1% | 02 Dec, 2022 |
| 2 | Stephen C. Glover | Director | 78,851 | 0 | 78,851 | 9.5% | 03 Mar, 2025 |
| 3 | Gregory Gene Freitag | Director | 61,213 | 0 | 61,213 | 7.4% | 03 Mar, 2025 |
Each row is that insider’s most recently reported position, from Form 4 filings over the last 60 months — which is why this total does not tie to the quarterly series above, where a quarter counts only the insiders who filed in it. Shares held through a fund or institutional portfolio are counted on the institutional ownership page instead.
| Date | Insider | Position | Transaction | Shares | Price | Value | Shares Held After | Ownership |
|---|---|---|---|---|---|---|---|---|
| 18 Oct, 2026 | Deborah Ramsdell | Director | Acquired A | 22,700 | $0.00 | $0 | 22,700 | Direct |
| 18 Oct, 2026 | Bruce Wendel | Director | Acquired A | 22,700 | $0.00 | $0 | 22,700 | Direct |
| 12 Jan, 2026 | Stephan Toutain | Chief Operating Officer | Acquired A | 300,000 | $0.00 | $0 | 300,000 | Direct |
| 12 Jan, 2026 | Kirk V. Shepard | Chief Medical Officer | Acquired A | 300,000 | $0.00 | $0 | 300,000 | Direct |
| 12 Jan, 2026 | Otis W Brawley | Director | Acquired A | 54,876 | $0.00 | $0 | 54,876 | Direct |
| 12 Jan, 2026 | Kamil Ali-Jackson | Director | Acquired A | 54,876 | $0.00 | $0 | 54,876 | Direct |
| 12 Jan, 2026 | Frank Bedu-Addo | President/Ceo | Acquired A | 548,782 | $0.00 | $0 | 548,782 | Direct |
| 12 Jan, 2026 | Gregory Conn | Chief Scientific Officer | Acquired A | 150,000 | $0.00 | $0 | 150,000 | Direct |
| 12 Jan, 2026 | Stephen C. Glover | Director | Acquired A | 54,876 | $0.00 | $0 | 54,876 | Direct |
| 12 Jan, 2026 | Spencer D. Brown | Senior Vp, General Counsel | Acquired A | 300,000 | $0.00 | $0 | 300,000 | Direct |
| 12 Jan, 2026 | Gregory Gene Freitag | Director | Acquired A | 54,876 | $0.00 | $0 | 54,876 | Direct |
| 12 Jan, 2026 | Lars Boesgaard | Chief Financial Officer | Acquired A | 300,000 | $0.00 | $0 | 300,000 | Direct |
| 12 Jan, 2026 | Ilian Iliev | Director | Acquired A | 54,876 | $0.00 | $0 | 54,876 | Direct |
| 12 Jun, 2025 | Stephan Toutain | Chief Operations Officer | Acquired A | 150,000 | $0.00 | $0 | 150,000 | Direct |
| 12 Jun, 2025 | Kirk V. Shepard | Chief Medical Officer | Acquired A | 150,000 | $0.00 | $0 | 150,000 | Direct |
| 12 Jun, 2025 | Lars Boesgaard | Chief Financial Officer | Acquired A | 150,000 | $0.00 | $0 | 150,000 | Direct |
| 11 Jun, 2025 | Ilian Iliev | Director | Acquired A | 22,700 | $0.00 | $0 | 22,700 | Direct |
| 11 Jun, 2025 | Kamil Ali-Jackson | Director | Acquired A | 22,700 | $0.00 | $0 | 22,700 | Direct |
| 11 Jun, 2025 | Gregory Gene Freitag | Director | Acquired A | 22,700 | $0.00 | $0 | 22,700 | Direct |
| 11 Jun, 2025 | Stephen C. Glover | Director | Acquired A | 22,700 | $0.00 | $0 | 22,700 | Direct |